That’s Bill Wilson, the cofounder of Alcoholics Anonymous (AA).
It was August 29, 1956.
Several hours earlier, he had ingested a dose of LSD.
But this wasn’t the kind of “acid trip” hippies went on in the 1960s.
And Bill W. – as AA members called him, following the group’s tradition of anonymity – was in the Veterans Affairs hospital in Los Angeles. Like most people who took LSD and other psychedelics in the 1950s, he was under supervision of a doctor.
Wilson’s experience in L.A. that day holds the secret to what Teeka Tiwari calls his next “trillion-dollar trade” – the use of psychedelics as a medicine for the mind.
First, it’s important you know how the cofounder of AA – a group not known for its love of mind-altering drugs – ended up seeking answers from LSD.
And he had made it his life’s work to help get others off booze, too.
LSD – which a Swiss chemist first synthesized 18 years earlier – was still legal. There was a lot of research on it happening at the time. And Wilson was curious whether the compound could terrify alcoholics into kicking their habit.
But after his experience, he saw it wasn’t terror, but the “awakening” LSD delivered, that made it a potential breakthrough treatment for alcohol addiction.
Wilson also had bouts of crippling depression. Following his trip, he reported a noticeable improvement. As he wrote…
I am certain that the LSD experience has helped me very much. I find myself with a heightened color perception and an appreciation of beauty almost destroyed by my years of depression…
But despite Wilson’s positive experience with LSD, other influential AA members opposed it.
Then in 1970, President Nixon signed the Controlled Substances Act into law in the U.S. Essentially, he wanted to criminalize his political opponents. So the act banned LSD and several other psychedelics and drove them underground.
This effectively banned research into these compounds, too. And Wilson’s ideas about their therapeutic potential faded from memory.
That’s according to Professor David Nutt.
He’s a psychiatrist, neuroscientist, and leading expert on drugs’ effects on the brain.
He’s also the director of the Neuropsychopharmacology Unit in the Division of Brain Sciences at Imperial College London. And he worked for the British government, advising it on drug laws.
As Nutt points out, Nixon banned psychedelics in the face of opposition from research funded by more than 130 National Institutes of Health (NIH) grants. That’s the primary medical research agency in the U.S.
This government-funded research covered more than 1,000 published papers and psychedelics trials involving 40,000 volunteers.
And it showed that LSD and other psychedelic compounds were effective in treating addiction, depression, and anxiety. Nutt…
[T]he drugs that have been most vilified and which we’ve been taught are the most dangerous, turned out to be the least dangerous.
The feds license and tax alcohol and opioids. These are two of the drugs that most harm society, according to Nutt’s research.
Meanwhile, the government drives LSD and other psychedelics underground. Even though the research it funded shows these drugs are not only safe, but also have massive therapeutic potential.
Politicians do a lot of dumb, self-serving things. But this comes close to the top of the list.
It was the most rigorous clinal trial to date assessing the therapeutic potential of a psychedelic compound.
It compared two sessions of therapy with psilocybin – the active compound in “magic mushrooms” – versus a six-week course of a leading antidepressant called escitalopram in 59 people with moderate to severe depression.
If you don’t recognize the name, escitalopram is sold under the brand names Cipralex and Lexapro.
The results of Nutt’s study were published in The New England Journal of Medicine. They revealed that, while depression decreased in both groups, the reductions in the psilocybin group were more significant and happened faster.
They’re working to develop even better psychedelic treatments for depression, anxiety, addiction, and PTSD (post-traumatic stress disorder).
If trial data keeps showing psychedelics are more effective than pharmaceutical alternatives… it’ll be one of the biggest medical breakthroughs of our lifetimes.
It’s so big, Teeka calls it the next trillion-dollar trade. In other words, it’s the next stock sector to start off tiny and explode to a $1 trillion valuation.
That means outsized gains for folks who invest in best-in-breed psychedelic stocks today. Teeka…
We’re at the cusp of a new trend the likes of which I haven’t seen in years. It’ll change the lives of millions of people around the world.
It’ll save lives. So it’s not a matter of if, but when we see more approvals from various agencies.
As these dominoes fall, early investors stand to make a fortune from psychedelic treatments.
Zappy is a futurist, multimillionaire, investor, and former Wall Street vice president.
And he’s spent the last 15 years researching psychedelic medicines and their therapeutic powers.
Now, athletes, movie stars, and world-class doctors consider him their most trusted source of information on this emerging trend.
For example, Zappy has helped Lamar Odom, the former NBA superstar, break his addictions and lifelong anxiety using psychedelic therapies.
And Zappy is sure of one thing…
So if you’re looking for an opportunity to get into an asset class early on – like Teeka did with crypto – keep this one on your radar.
Here’s Zappy with more…
E-commerce… cryptocurrency… cannabis… These have proven to be incredible new asset classes. But psychedelics – with the remarkable medical and mental health benefits they’ve already proven they create, as well as the groundbreaking research and legal changes coming in the near future – are poised to be the biggest one yet.
That’s why I decided to team up with Teeka and Legacy Research. I want to help regular investors take a piece of this new industry and the enormous returns that await.
Right now, individual investors have the early advantage over institutions, which can invest only in companies on major exchanges.
And despite the early moves psychedelic stocks have already made, there’s still plenty more upside. A slew of new companies are coming to market this year, some of which will be blockbusters.
Teeka couldn’t agree more…
We aren’t even in the early innings of this trend… The game hasn’t started yet. Eventually, we’ll find startups in this space that can turn tiny grubstakes into life-changing gains.
Your best option is to follow Teeka and Zappy at our Palm Beach Special Opportunities advisory.
You can find out more about how to do that here.
It’s where they recommend the best-in-breed psychedelic medicine stocks set to benefit as this trend takes off.
Your second-best option is to buy shares in the Defiance Next Gen Altered Experience ETF (PSY).
It holds a basket of 22 companies working on psychedelic and cannabis-based therapeutics.
The potential for gains is huge. But there’s a risk that some therapies will fail to reach the mass market.
So make sure to treat psychedelic medicine stocks as speculative positions in a well-balanced portfolio. And don’t invest more than you can afford to lose.
Regards,
Chris Lowe
December 2, 2021
Dublin, Ireland